Moderna's Covid-19 Vaccine Moves to Bigger Study
Source: Wall Street Journal
New details about the first human study of Moderna Inc.’s experimental coronavirus vaccine emerged Tuesday, which researchers said reinforced their decision to take the shot into a large, decisive clinical trial scheduled to start in late July.
The new results, published online by the New England Journal of Medicine, showed that the vaccine induced the desired immune response for all 45 people evaluated—a larger group than in the preliminary data Moderna released in May—and was generally safe and well-tolerated.
“This is really quite good news,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in an interview Tuesday. NIAID co-developed the Moderna vaccine and led the study. “The gold standard of protection against a viral infection is neutralizing antibodies,” he said. “And the data from the study, small numbers as it may be, are pretty clear that this vaccine is capable of inducing quite good [levels] of neutralizing antibodies.”
Researchers said they found no serious safety risks, though some participants had injection-site pain and symptoms such as fatigue, headache and chills.
Read more: https://www.msn.com/en-us/news/us/modernas-covid-19-vaccine-moves-to-bigger-study/ar-BB16JEoR?li=BBnb7Kz
= new reply since forum marked as read
The summary conclusion from the paper in the New England Journal of Medicine
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483?query=featured_home
